The FDA cleared PrecivityAD2, a blood test designed to detect Alzheimer’s-linked amyloid pathology, positioning it as an aid in evaluating Alzheimer’s disease. The move adds a new objective layer for clinicians working through disease staging when imaging or invasive tests are not immediately available. A randomized model of how to improve home care for cancer therapy also landed, with telemedicine-supported home injections reducing the practical burden for breast cancer patients receiving injectable GnRH agonist therapy. The study published in JAMA Network Open highlights operational shifts that can reduce clinic visits without changing treatment intent. In imaging, researchers advanced more reliable measurement pipelines for medical imaging guidance—an increasingly central need as scans turn into quantitative decision tools rather than only visual aids. Such work is aimed at improving how tumors are tracked and how response is assessed during treatment.